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Abstract Darunavir, an anti-HIV drug having poor solu-
bility in aqueous and lipid medium, illustrates degradation
above its melting point, i.e. 74 C, thus, posing a challenge
to dosage formulation. Despite, the drug suffers from poor
oral bioavailability (37%) owing to less permeability and
being poly-glycoprotein and cyp3A metabolism substrate.
The study aimed formulating a SLN system to overcome
the formulation and bioavailability associated problems of
the drug. Based on the drug solubility and stable dispersion
findings, lipid and surfactant were chosen and nanoparti-
cles were prepared using hot-homogenization technique.
Optimization of variables such as lipid concentration, oil-
surfactant and homogenization cycle was carried and their
effect on particle size and entrapment efficiency was
studied. Freeze-dried SLN further characterized using
SEM, DSC and PXRD analysis revealed complete entrap-
ment of the drug and amorphous nature of the SLN. In vitro
pH release studies in 0.1 N HCl and 6.8 pH buffer
demonstrated 84 and 80% release at the end of 12th h. The
apparent permeability of the SLN across rat intestine was
found to be 24 9 10-6 at 37 C at the end of 30 min while
at 4 C the same was found to be 5.6 9 10-6 prompting
involvement of endocytic processes in the uptake of SLN.
Accelerated stability studies revealed no prominent chan-
ges upon storage.
Keywords Darunavir  Nanoparticles  High-pressure
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Introduction
It is seen mostly that the in vitro data do not co-relate with
those obtained in vivo and themain reason for this happens to
be insufficient or poor absorption, rapid metabolism and
elimination, e.g. peptidic drugs, distribution of the drug to
accompanying tissues (cancer drugs), low aqueous solubility
of drugs, high fluctuation in plasma levels of drug which is
due to unpredictable bioavailability after peroral adminis-
tration, and effect of presence of food on plasma levels.
A promising strategy to overcome the aforementioned
problems encompasses development of suitable drug car-
rier systems with potential of releasing the active com-
pound according to the specific requirements of the
undergoing therapy. Solid lipid nanoparticles (SLN) not
only combine the advantages of colloidal drug carrier
systems such as liposomes, polymeric nanoparticles and
emulsions but also avoid drawbacks associated with these
systems (Chalikwar et al. 2012).
Darunavir, a non-peptidic protease inhibitor, suffers
from poor oral bioavailability (37%) as it acts as a substrate
for polyglycoprotein (PgP) which causes efflux of the
absorbed drug back into the intestinal lumen and also a
substrate for cyp3A metabolism (Vermeir et al. 2009). The
bioavailability of darunavir can be increased to 82% by co-
administering ritonavir, which is a potent cyp3A inhibitor.
Present work attempts to improve bioavailability of
darunavir by formulation as lipid nanoparticulates, as these
have been reported to improve oral bioavailability of drugs
prone to PgP efflux and CYP-mediated first-pass metabo-
lism (Aji Alex et al. 2011). Darunavir degrades at a tem-
perature above its melting point (74 C) which happens to
be a big hurdle in preparation of darunavir SLN by hot
emulsification method. To circumvent this, a lipid mixture,
melting at temperature less than that of darunavir’s melting
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point, was used to formulate the SLN. It is believed that the
SLN would be taken up by the lymphatic system owing to
the lipid carrier and the lipid matrix and bypass the hepatic
metabolism and also reduce the PgP efflux (Aji Alex et al.
2011). The novelty of the work lies in successful prepa-
ration and characterization of a non-lipidic, temperature
degradable anti-HIV drug into a SLN carrier and demon-
stration of improved permeability of the same.
Materials and method
Materials
Darunavir and glyceryl caprylate were received as a kind
gift from Lupin Research Park, Pune and all other chemi-
cals were procured from the local sources.
Methods
Selection of lipid
Selection of lipid for preparation of SLN was done on the
basis of maximum solubility of drug in lipid. The solubility
of darunavir was evaluated in various lipids such as glyc-
eryl monostearate, Compritol ATO 88, Gelucire 43/01,
Precirol ATO5, Glyceryl caprylate. Darunavir (50 mg) was
weighed accurately and transferred to 50 mg of melted
lipid (melting point corresponding to respective lipids)
with continuous stirring. Further incremental amount of
lipid was added in portions under continuous stirring and
heating till a clear solution was formed. The total amount
of lipid added to get a clear solution was recorded.
Selection of the surfactant system
The surfactant system was chosen depending upon the
average diameter of the particle produced and polydisper-
sity index (PDI) of the resultant SLN dispersion by the
surfactant system. Different combinations of lipid- and
water-soluble surfactants were employed (Table 1).
Briefly, lipid was taken in a ratio of 5 times that of dar-
unavir, melted at 55 C and lipid surfactant (2%) was added
to this melt, aqueous phase was prepared by dissolving
water-soluble surfactant (2%) into distilled water. The two
phases were mixed at the same temperature followed by
stirring under an over-head stirrer at 15,000 rpm for 1 min to
obtain a uniform emulsion,whichwas further passed through
a high-pressure homogenizer (HPH) keeping pressure at 500
bars. The resultant SLN was evaluated for PS and PDI.
Experimental design
A Box–Behnken Design containing 15 experimental runs to
evaluate three variables, viz., drug to lipid ratio, concentra-
tion of lipid phase surfactant and number of homogenization
cycles at 3 levels was employed to determine their effect on
two responses, i.e. entrapment efficiency (EE) and particle
size (PS) and their interaction therein. The layout of the
experimental design and factor coding is shown in Table 2.
The low, medium and high levels of lipid were (1.5, 2.5,
3.5 g), Span 80 was (1, 2, 3%) and homogenization cycles
was (1, 3, 5), respectively.
Preparation of SLN
The SLNs were prepared using HPH, as described in
selection of surfactant system section. The drug was dis-
solved in 1 ml of GC, heated to temperature of lipid phase
and then added to the lipid phase.
Determination of PS
The PS analysis of the prepared Darunavir SLN dispersion
was performed using Malvern zetasizer ZS 90 (Malvern
Instruments, Worcestershire, UK). The mean diameter and
the poly dispersity index of each batch were recorded.
Determination of EE
Darunavir SLN dispersion was subjected to centrifugation
at 20,000 rpm and the pellet of settled SLN was separated
Table 1 PS and PDI of nanoparticles with different surfactant combinations
Batches Lipid phase surfactant (2%) Water phase surfactant (2%) PSa (nm) PDIa
S1 Span 80 SLS 230 ± 12 0.935 ± 0.0961
S2 Span 80 Poloxamer 188 203 ± 25 1.250 ± 0.195
S3 Span 80 Tween 80 346 ± 3 0.280 ± 0.050
S4 Soya lecithin SLS 105 ± 19 1.156 ± 0.145
S5 Soya lecithin Poloxamer 188 746.3 ± 8.3 0.92 ± 0.0854
S6 Soya lecithin Tween 80 2017 ± 15 1.044 ± 0.129
a n = 3 ± SD
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from supernatant. The pellet was analysed for the drug
content spectrophotometrically at k 262 nm using chloro-
form as a solvent; similarly the supernatant was analysed
for unentrapped darunavir spectrophotometrically at k 267
using methanol as a solvent. EE was calculated according
to the following equation:
EE% ¼ The amount of entrapped drug in SLN
The total amount of drug
 100:
ð1Þ
Freeze drying of SLN
The optimized nanosuspension was mixed with various
matrix formers such as mannitol, sucrose, microcrystalline
cellulose and aerosil in concentrations 50, 100 and 200%
w/w to drug (Table 3) and subjected to deep freezing near
-20 C temperature for a period of 24 h. The frozen
nanoparticulate dispersion was subjected to lyophilization
at room temperature and 0.002 mbar vacuum using Lab-
conco freezone 2.5 lyophilizer (USA).
Evaluation of freeze-dried SLN
PS measurement
The freeze-dried SLNs were suspended in double-distilled
water for the PS analysis, which was determined as dis-
cussed in determination of PS section.
Drug content
For determining the drug content, 100 mg of freeze-dried
SLN was weighed accurately and transferred to a 50-ml
conical flask, followed by addition of 10 ml of chloroform
and sonication for 10 min. The following solution was
filtered and analysed spectrophotometrically at k 262 nm
for drug content. The %EE and %drug loading were
determined using the following formulae, respectively.
EE% ¼ Practical yield
Theoretical yield
 100 ð2Þ
%Drug loading ¼ The amount of entrapped drug in SLN
The total weight of SLN
 100
ð3Þ
Table 2 Experimental run and responses for optimization of darunavir SLN formula using Box–Behnken design
S. no. Factor 1(A): lipid
(g)
Factor 2(B): Span 80
(%)






F1 3.5 2 5 208 ± 4 12 ± 4
F2 1.5 3 3 248 ± 2 25 ± 2
F3 3.5 3 3 242 ± 3 6 ± 3
F4 3.5 2 1 276 ± 1 25 ± 5
F5 1.5 2 1 238 ± 5 62 ± 2
F6 2.5 1 1 244 ± 2 62 ± 3
F7 2.5 1 5 230 ± 3 24 ± 2
F8 1.5 1 3 197 ± 5 56 ± 5
F9 2.5 2 3 228 ± 2 10 ± 4
F10 1.5 2 5 181 ± 5 66 ± 3
F11 2.5 3 5 183 ± 3 2 ± 5
F12 2.5 3 1 255 ± 2 30 ± 2
F13 3.5 1 3 267 ± 4 21 ± 6
a n = 3 ± SD
Table 3 Observations of various matrix formers in different con-
centrations used for freeze drying
S. no. Matrix former Conc.
(% w/v to drug)
Observations
1 Sucrose 50 Sticky powder
2 Sucrose 100 Sticky powder
3 Sucrose 200 Sticky powder
4 Mannitol 50 Sticky powder
5 Mannitol 100 Sticky powder










10 Aerosil 50 Sticky powder
11 Aerosil 100 Free-flowing powder
12 Aerosil 200 Free-flowing powder
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Surface morphology by surface electron microscopy (SEM)
The freeze-dried SLNs were sputtered with platinum in an
ion sputter for 300 s. Images were collected at an accel-
eration voltage of 15 kV using a back-scattered electron
detector on Joel JSM 6360 SEM, USA. Analysis was
performed at 25 ± 2 C.
Zeta potential (ZP) measurement
Zeta potential was determined by measuring the elec-
trophoretic mobility using Malvern Zetasizer Nano ZS 90
(Malvern Instruments, UK). The field strength applied was
20 V cm-1. Prior to the measurement, all samples were
diluted in distilled water.
Differential scanning calorimetry (DSC)
Differential scanning calorimetry thermograms for dar-
unavir SLN, bulk darunavir, bulk lipid and physical mix-
ture of lipid and darunavir were generated using DSC823
Mettler Toledo, Mettler Ltd. About 10 mg of sample was
weighed and transferred into aluminium pan which was
further crimp sealed. The pans were subjected to heating,
using an empty pan as reference; over a temperature range
of 30 to 300 C with heating rate of 10 C per min. Inert
atmosphere was provided by purging nitrogen gas flowing
at a rate of 40 ml/min.
X-ray diffractometry (XRD)
X-ray scattering measurements were carried out using
X-ray diffractometer (PW 3710, Philips Ltd.). A Cu–Ka
radiation source was used with the scanning rate (2 h/min)
of 5 C per min. X-ray diffraction measurements were
carried out on darunavir SLN, bulk darunavir, bulk lipid
and physical mixture of lipid and darunavir.
Effect of pH on in vitro release of darunavir
The effect of pH on the release array of the drug from SLN
was evaluated by performing dissolution studies separately
in 0.1 N HCl and phosphate buffer with 6.8 pH for 12 h
using USP dissolution apparatus (Type II) at 37 ± 2 C
and 50 rpm. The SLN was filled in HPMC capsule and the
same was used in dissolution vessel. Aliquots were with-
drawn at 1, 2, 3, 4, 6, 8, 10 and 12 h intervals using a 0.2-
lm filter (PS of SLN ranged 266–274 nm) and analysed
spectrophotometrically at 264 nm to determine the drug
content. The kinetics of drug release was studied using PCP
disso software.
Ex vivo permeability study
Permeability of the prepared SLN across rat intestine was
evaluated using everted rat intestine model (Zhang et al.
2012). One end of the isolated intestine everted using glass
rod was clamped and secured with a silk suture, while from
the other open end 1 ml of phosphate buffer, pH 6.8, was
filled using a syringe. The proximal end was then carefully
secured using silk suture and the resultant sac was incu-
bated at 37 C in dispersion of bulk darunavir (effective
concentration of 5 lg/ml) and at 37 and 4 C in dispersion
of darunavir SLN (effective concentration equivalent to
5 lg/ml) for 0.5 h and the fluid in the lumen was analysed
for drug content spectrophotometrically at 267 nm.
Accelerated stability studies
The freeze-dried SLNs were stored in capped glass vials at
40 ± 2 C/75 ± 5% RH for a period of 90 days. Samples
were withdrawn at the end of 0, 30, 60 and 90 days to




None of the drug lipid combinations displayed clarity despite
increasing the amount of lipid up to 500 mg whereas the
solubility of the drug in glyceryl caprylate (GC)was found to
be 500 mg/ml. The attempt to make a melt dispersion of
darunavir in GMS also failed because of degradation beyond
melting point (74 C); hence, a solution of darunavir in GC
was prepared (500 mg/ml) and was added to molten GMS
maintained at melting point 65 C to yield clear solution.
Selection of the surfactant system
Table 1 represents findings from different amalgamations
of lipid- and water-based surfactant. Tween and Span
combination seemed to provide nanoparticles with ade-
quate size and PDI.
Experimental designs
The experiments were designed to study the effect of three
independent variables, namely lipid and surfactant concen-
tration and number of homogenization cycle at three levels
on response variable PS and percentage entrapment. The
batches of Box–Behnken design are represented in Table 2.
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Preparation of SLN
SLNs were prepared using HPH as described in the
selection of surfactant system section.
Determination of PS
The range of PS distribution was found to be 181–276 nm.
The PS of each batch is summarized in Table 2.
Determination of EE
The outcomes of the EE determination are summarized in
Table 2. The range of the percentage entrapment was found
to be 2–66%. The low EE can be attributed to the nature of
the drug (logP 1.76) and its insolubility in GMS.
Optimization data analysis
The formulations prepared as per the experimental design
were evaluated and the analysis of experimental results was
done using the Stat-Ease Design Expert. The ANOVA,
P value and model F value for PS and percent drug
entrapment were obtained (Table 4).
F value for both models was found to be high which
indicated that the models were significant. P value less than
0.05 indicated that the model terms were significant. High
R2 values indicated good agreement between formulation
variables and response parameters.
The statistical model generated for PS was:
PS ¼ 228þ 16:13 Að Þ  9 Bð Þ  21:50 Cð Þ  19 ABð Þ
 2:75 ACð Þ  14:5 BCð Þ þ 4:13 A2 
þ 6:38 B2  6:38 C2 þ 15:50 A2B  9:75 A2C 
The statistical model generated for EE was:
R2 ¼ 10 22:75 Að Þ  12:5 Bð Þ  16:5 Cð Þ þ 4 ABð Þ
 4:25 ACð Þ þ 14:38 A2 þ 2:63 B2 þ 16:88 C2 
þ 14:25 A2C þ 9:25 AB2 
The solution provided by the Design Expert software
was, lipid concentration (1.5 g), homogenization cycle (1)
and Span (1%), the same had a desirability value of 0.946
towards obtaining optimum parameters for the preparation
of SLN. To prove the reliability of the statistics,
verification run was carried out further. The optimized
formulation had an average PS of 210 nm and EE of
74.23% and in response to the predicted values of
204.5 nm and 71.84% by the software. The percentage
error was ?3.32 and ?2.68% for PS and percentage
entrapment, respectively.
Freeze drying of SLN
To facilitate the freeze drying and obtain free-flowing
powder without significant increment in PS various matrix
formers were used in different concentration as tabulated in
Table 3.
Formulations 11 and 12 were obtained with non-sticky
powder. Formulation 11 was selected as final formulation
as it employed lower amount of matrix former.
Evaluation of freeze-dried SLN
PS measurement
The freeze-dried darunavir SLNs were subjected to PS
measurement. An increase in the PS (270 nm) as compared
to the size prior to freeze drying (210 nm, D90: 204 nm)
was noted.
Drug content
Post-freeze drying, the content of the darunavir in the SLN
was decreased from 74.23 to 69.8%. In addition, post-freeze
drying the % loading efficiency was found to be 9.37%.
Surface morphology
Surface electron microscopy images revealed presence of
smooth, spherical morphology of the SLN (Fig. 1).
Table 4 ANOVA output of the Box–Behnken design for optimiza-
tion of darunavir SLN
S. no. Outcomes R1 PS R2 EE
1 F value 8015.35 37.75
2 P value 0.0087 0.0261
3 R2 value 0.9865 0.9947
4 Adequate precision 278.936 17.530
Fig. 1 SEM image of freeze-dried SLN
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Zeta potential measurement
The zeta potential of the freeze-dried SLN was found to be
-22 ± 2 mv (n = 3, ±SD), which is desired as negative
charge particles are favoured for lymphatic uptake.
Differential scanning calorimeter (DSC)
Differential scanning calorimeter thermograms for dar-
unavir, bulk GMS, physical mixture of darunavir and GMS
and Darunavir SLN are represented in Fig. 2.
X-ray diffractometry (XRD)
X-ray diffractograms for bulk darunavir, bulk GMS and
darunavir SLN are represented in Fig. 3.
Effect of pH on in vitro release of drug
Darunavir SLN was subjected to dissolution study in dif-
ferential media, i.e. simulated gastric fluid SGF (0.1 N
HCl) and simulated intestinal fluid (SIF) (pH 6.8), both
drug release profiles (Fig. 4) were sustained till 12 h (84
and 80% release, respectively). The release of drug from
SLN in 0.1 N HCl followed Korsmeyer–Peppas model
with r2 = 0.9816 and n value = 0.851 while the release in
6.8 pH buffer followed zero-order release with
r2 = 0.9759. The slight higher release of darunavir in SGF
can be attributed to higher solubility of the same in acidic
media.
Ex vivo permeability study
At the end of 30 min, the permeability of bulk darunavir in
everted rat intestine model was found to be 2.1 9 10-6 cm/
s at 37 C and 1.9 9 10-6 cm/s at 4 C while the apparent
permeability of the SLN was found to be 24 9 10-6 cm/s
at 37 C and 5.6 9 10-6 cm/s at 4 C.
Accelerated stability studies
Stability estimation of the freeze-dried SLN was done on the
basis of PS, EE and zeta potential. Results showed no sig-
nificant changes in any of the assessed parameters. The find-
ings of accelerated stability study are represented in Table 5.
Discussion
Selection of lipid
Glyceryl caprylate, chemically glyceryl mono–di-capry-
late, is known for its high solubilization capacity owing to
its low molecular volume and natural surfactant enhancer
Fig. 2 DSC thermograms for
A darunavir, B bulk GMS,
C physical mixture of darunavir
and GMS and D darunavir SLN
Fig. 3 X-ray diffractograms for
darunavir, bulk GMS and
darunavir SLN
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activity. The presence of hydroxyl group also plays an
important role in solubility of drugs like darunavir in GC
(Prajapati et al. 2012). GC, here was used as a co-solubi-
lizer to enhance the solubility in the GMS medium.
Selection of the surfactant system
SLN containing sodium lauryl sulphate (SLS) produced
substantially smaller PS, but owing to the toxicity profile
(Rowe et al. 2009), high polydispersity index and associ-
ated instability of the suspending property, it was elimi-
nated as a choice. Soya lecithin and other combinations of
water-soluble surfactants produced particles with high
diameter with a high PDI value. The combination of Span
80 and Tween 80 resulted in particles of diameter 346 nm
and PDI of 0.280 and hence this system was chosen to
carry the study further. Tween as a long-chain surfactant
provides aqueous phase stability to the emulsions formed
while Span provides the necessary stabilization for the
lipidic phase into the continuous aqueous phase thus
leading to the formation of an emulsion system of which
low PS and PDI is a functional characteristic.
Experimental designs
A three-factor, three-level design would require a total of
27 experimental runs without any repetitions and a total of
30 runs with 3 repetitions (Solanki et al. 2007). A Box–
Behnken experimental design reduces the number of
experiments to 15, hence was found convenient and
appropriate for the study.
Preparation of SLN
It was believed that the aqueous phase would emulsify the
lipid phase containing solubilized drug when both phases
mixed under stirring and the so-formed pre-emulsions
would further be reduced to nanoemulsions under pressure
provided by HPH. The resultant when cooled would form
SLN incorporated with drug.
Determination of PS
The decrease in the PS can be attributed to the breaking of
larger droplets into smaller ones under pressure provided
by HPH along with the HLB provided by the Tween and
Span 80 surfactant system.
Determination of EE
As the amount of lipid increases the ratio of GC in which
drug is dissolved lower in comparison to GMS leading to
expulsion of drug, also the magnitude of the pressure from
HPH surfactant system lowering PS causes migration of the

























Fig. 4 In vitro release profile of
darunavir SLN in SGF and SIF
(n = 6)
Table 5 Stability study data for freeze-dried darunavir SLN
S. no. Parameters 0 Days 30 Days 60 Days 90 Days
1 PSa 270 ± 3 nm 270 ± 2 nm 271 ± 3 nm 270 ± 4 nm
2 EEa 69.8 ± 0.4% 69 ± 0.2% 68.3 ± 0.3% 68 ± 0.6%
3 Zeta potentiala -22 ± 1 mv -22 ± 1 mv -22 ± 2 mv -22 ± 1 mv
a n = 3 ± SD
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Optimization data analysis
The model indicates that lipid at higher concentration
contributes in building the PS which may be due to
increasing viscosity of the system owing to the fact that
increased lipid concentration span had a limited effect of
reducing the PS, (Pachuau and Mazumder 2009; Gadhiri
et al. 2012; Huang et al. 2008) whereas number of
homogenization cycle had most dominant effect which is
due to the increased shear provided to break the globules.
The interaction term AB, i.e. when lipid and Span are
increased simultaneously, caused reduction in the PS which
can be attributed to smaller hydrophilic head of span
(Gadhiri et al. 2012). The interaction term AC, i.e. when
lipid and homogenization cycles were increased together,
caused moderate decrease in the PS which may be due to
the presence of lipid. The interaction term BC i.e. when
Span and homogenization cycles were increased, caused
pronounced decrease in the PS which is because both the
factors are responsible for reduction of PS. The interaction
terms A2 and B2 which are higher order terms increase PS,
as lipid builds larger particles but when only Span is
increased beyond a limit, its lipoid nature also contributes
to increasing PS. Increasing the homogenization cycles by
any magnitude always had the same effect of reducing the
PS. Similar effect was shown by the response surface plots
generated (Figs. 5, 6, 7).
The model indicates that the lipid contributes to the
decrease in the EE which is contrary to the general
observation, this can be explained with the understanding
of lowering of GC:GMS ratio with increase in GMS con-
tent with respect to ratio of GC which is fixed and increase
in the GMS causes lower availability of GC to keep drug in
solution leading to its expulsion and reduced entrapment.
Fig. 5 Response surface plot
showing influence of Span and
lipid on PS
Fig. 6 Response surface plot
showing influence of lipid and
number of homogenization
cycle on PS
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Hence, there arises a need to optimize the lipid content.
The role of the surfactant concentration and homogeniza-
tion cycle is seen to contribute to reduction of drug
entrapment which is because of lower PS of globule
leading to enhanced area for migration of drug to aqueous
phase. However, the interaction between lipid and surfac-
tant (AB) led to increase in the EE due to contribution of
Span in lipid phase. The interaction between lipid and
homogenization cycle (AC) shows a minor decrease in the
entrapment which is due to the counteraction of the effect
of homogenization by increased presence of lipid. The
higher order terms, i.e. A2, B2 and C2 indicate increase in
the EE. Similar effects were shown by the response surface
plots generated (Figs. 8, 9).
Freeze drying of SLN
Sucrose and mannitol provided cryoprotection in concen-
tration ranges of 100 and 200% but the lyophilized powder
retained stickiness immediately after removal of samples
which may be due to hygroscopic nature of the sugars.
Thus, it was eliminated as a choice.
Evaluation of freeze-dried SLN
PS measurement
The increase in the PS post-freeze drying could be because
of the fusion of particles and/or polymorphic transition of
Fig. 7 Response surface plot
showing influence of number of
homogenization cycle and Span
on PS
Fig. 8 Response surface plot
showing influence of lipid and
Span on percent entrapment
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the lipid (transformation of higher energy a and b0 modi-
fication to the lower energy b modification) in the process
of being lyophilized (Liu et al. 2014).
Drug content
The reason for the decrease of darunavir content in
nanoparticulates could be polymorphic transition of the lipid
leading to expulsion/leaking/leaching of drug from the SLN
during the progression of freeze drying (Liu et al. 2014).
Surface morphology
The spherical and smooth nature of the particle is often
favoured for the uptake through the cells of the lymphatic
tissue owing to the ease of uptake of the spherical particles
as compared to the uneven and disfigured particles
(Champion et al. 2007).
Zeta potential measurement
The negative charge on the surface of the nanoparticle is
believed to facilitate uptake from the intestine by the
Payers patch, leading to the lymphatic circulation, also it is
believed to prevent entangling of the nanoparticles in the
negatively charged mucous owing to the repulsion of like
charges (Kovacˇevic´ et al. 2014).
Differential scanning calorimeter (DSC)
A sharp peak at 85 C for darunavir (A) followed by further
peaks representing the polymorphic behaviour, peak at 60 C
representing the melting of GMS (B) and two individual
peaks at 60 and 85 C for physical mixture of darunavir and
GMS indicating absence of any interaction between the two
were seen. The thermogram for darunavir SLN showed a
single broad peak at 55 C indicatingmolecularmixing of the
amorphous drug with the lipid GMS. The decrease in the
melting temperature can be explained to be a result of con-
version ofGMS into stable b form during heating and cooling
operations in SLN preparation (Souto et al. 2008).
X-ray diffractometry (XRD)
X-ray diffractograms for darunavir and GMS exhibited
sharp crystalline peaks which are absent in the diffrac-
togram of darunavir SLN, indicating complete molecular
level miscibility of the drug in the GMS and presence of
the drug in amorphous form (Ravi et al. 2014).
Effect of pH on in vitro release of drug
The reason for the comparatively higher release of darunavir
in 0.1 N HCl can be attributed to the increased solubility of
darunavir in acidic medium. Figure 4 represents the release
profile of darunavir in 0.1 NHCl and 6.8 pH. InHCl, the SLN
followedKorsmeyer–Peppasmodelwith an ‘n’ value of 0.851
meaning an anomalous release mechanism combining diffu-
sion and erosion while in 6.8 pH the release was of zero order.
Ex vivo permeability study
At 4 C the endocytic processes are diminished which was
the reason for the decreased permeability of the SLN in the
Fig. 9 Response surface plot
showing influence of number of
homogenization cycle and lipid
on percent entrapment
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experimental sample kept at 4 C thus confirmed involve-
ment of endocytosis in uptake of darunavir SLN was
established (Ravi et al. 2014). The increased permeability
of the SLN over bulk drug can be attributed to the lipid
matrix in which drug is entrapped as lipid being favoured
for uptake by the M cells in the intestinal epithelium.
Accelerated stability studies
It is reported that, upon ageing, drug expulsion from solid
lipid matrix (due to crystallization of lipid) leads to
reduction in EE which being the reason for the decrease
%EE of SLN upon stability storage (Mu¨ller et al. 2011).
Conclusion
Darunavir SLN prepared by HPH method using Box–
Behnken design was found to have PS-270 nm, %EE
69.8% and smooth spherical surface. Ex vivo permeability
studies demonstrated endocytic uptake of the SLN thus
establishing the hypothesis that lymphatic transport can be
followed by the prepared SLN to increase the systemic
availability and the demonstration of the same is under
experimentation.
Thus, it can be concluded that HPH method can be
successfully employed to prepare darunavir SLN which is
believed to have potential to increase the systemic avail-
ability of the drug owing to endocytic uptake and lym-
phatic transport therein.
Future perspective
The authors believe that the future of the aforementioned
research work shall be evaluation of the impact of the
surface charge on the lymphatic uptake of SLN. The
research is believed to act as a platform technology for
delivery of drug molecules exhibiting low bioavailability
owing to extensive metabolism, especially, anti-retrovirals,
proteins and peptides.
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